(PACB) Pacific Biosciences of - Overview
Stock: Sequencing Systems, Consumable Kits, SMRT Technology, Revio, Sequel, SBB
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 99.8% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.56 |
| Alpha | -12.44 |
| Character TTM | |
|---|---|
| Beta | 1.673 |
| Beta Downside | 0.832 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.52% |
| CAGR/Max DD | -0.47 |
Description: PACB Pacific Biosciences of December 28, 2025
Pacific Biosciences (NASDAQ:PACB) designs and manufactures single-molecule, real-time (SMRT) sequencing platforms and consumables that enable long-read DNA analysis. Its product portfolio includes the Revio, Sequel, Sequel II/IIe instruments, associated SMRTbell library preparation kits, binding kits, and on-instrument reagents such as phospholinked nucleotides, as well as the newer SBB short-read system and related flow-cells.
Key performance indicators from the most recent 10-Q (Q3 2024) show FY 2023 revenue of approximately **$1.0 billion**, up **~15 % YoY**, driven primarily by a **30 % increase in Revio system sales** and higher consumable uptake in clinical-grade applications. Gross margin improved to **62 %** as the mix shifted toward higher-margin reagents, while cash on hand stood at **$450 million**, providing runway through FY 2025. The long-read sequencing market is projected to grow at **CAGR ≈ 12 %** through 2030, fueled by expanding demand for structural variant detection in oncology, rare-disease diagnostics, and agricultural genomics-trends that directly benefit PacBio’s technology.
From a risk perspective, PacBio faces **intense competition** from Illumina’s short-read dominance and Oxford Nanopore’s portable long-read devices; any acceleration in cost reductions or throughput gains by rivals could compress PacBio’s pricing power. Additionally, the company’s growth assumptions rely on continued **clinical adoption** of long-read assays, which remain subject to regulatory approvals and reimbursement pathways that are still evolving.
For a deeper, data-driven assessment of how PacBio’s valuation compares to sector peers, you might explore the analytical tools on **ValueRay**, which can help you model scenario-based outcomes without any commitment.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -503.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: 214.1% < 20% (prev 302.8%; Δ -88.63% < -1%) |
| CFO/TA -0.15 > 3% & CFO -122.8m > Net Income -503.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (300.8m) vs 12m ago 10.23% < -2% |
| Gross Margin: 25.40% > 18% (prev 0.21%; Δ 2519 % > 0.5%) |
| Asset Turnover: 13.72% > 50% (prev 11.94%; Δ 1.78% > 0%) |
| Interest Coverage Ratio: -62.13 > 6 (EBITDA TTM -103.4m / Interest Expense TTM 7.97m) |
Altman Z'' -14.66
| A: 0.41 (Total Current Assets 394.2m - Total Current Liabilities 63.2m) / Total Assets 803.2m |
| B: -3.31 (Retained Earnings -2.65b / Total Assets 803.2m) |
| C: -0.44 (EBIT TTM -495.2m / Avg Total Assets 1.13b) |
| D: -3.46 (Book Value of Equity -2.65b / Total Liabilities 767.1m) |
| Altman-Z'' Score: -14.66 = D |
Beneish M -3.74
| DSRI: 1.17 (Receivables 30.6m/29.4m, Revenue 154.6m/173.1m) |
| GMI: 0.84 (GM 25.40% / 21.25%) |
| AQI: 0.76 (AQ_t 0.43 / AQ_t-1 0.56) |
| SGI: 0.89 (Revenue 154.6m / 173.1m) |
| TATA: -0.47 (NI -503.6m - CFO -122.8m) / TA 803.2m) |
| Beneish M-Score: -3.74 (Cap -4..+1) = AAA |
What is the price of PACB shares?
Over the past week, the price has changed by -19.47%, over one month by -12.50%, over three months by +2.25% and over the past year by +13.75%.
Is PACB a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PACB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.4 | 33% |
| Analysts Target Price | 2.4 | 33% |
| ValueRay Target Price | 1.3 | -28% |
PACB Fundamental Data Overview February 03, 2026
P/B = 19.826
P/EG = -0.17
Revenue TTM = 154.6m USD
EBIT TTM = -495.2m USD
EBITDA TTM = -103.4m USD
Long Term Debt = 645.2m USD (from longTermDebt, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 703.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 646.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (682.3m + Debt 703.1m - CCE 298.7m)
Interest Coverage Ratio = -62.13 (Ebit TTM -495.2m / Interest Expense TTM 7.97m)
EV/FCF = -8.28x (Enterprise Value 1.09b / FCF TTM -131.3m)
FCF Yield = -12.08% (FCF TTM -131.3m / Enterprise Value 1.09b)
FCF Margin = -84.91% (FCF TTM -131.3m / Revenue TTM 154.6m)
Net Margin = -325.8% (Net Income TTM -503.6m / Revenue TTM 154.6m)
Gross Margin = 25.40% ((Revenue TTM 154.6m - Cost of Revenue TTM 115.3m) / Revenue TTM)
Gross Margin QoQ = 41.36% (prev 36.93%)
Tobins Q-Ratio = 1.35 (Enterprise Value 1.09b / Total Assets 803.2m)
Interest Expense / Debt = 0.25% (Interest Expense 1.74m / Debt 703.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -391.2m (EBIT -495.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.24 (Total Current Assets 394.2m / Total Current Liabilities 63.2m)
Debt / Equity = 19.48 (Debt 703.1m / totalStockholderEquity, last quarter 36.1m)
Debt / EBITDA = -6.25 (negative EBITDA) (Net Debt 646.6m / EBITDA -103.4m)
Debt / FCF = -4.93 (negative FCF - burning cash) (Net Debt 646.6m / FCF TTM -131.3m)
Total Stockholder Equity = 174.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.70% (Net Income -503.6m / Total Assets 803.2m)
RoE = -289.5% (Net Income TTM -503.6m / Total Stockholder Equity 174.0m)
RoCE = -60.46% (EBIT -495.2m / Capital Employed (Equity 174.0m + L.T.Debt 645.2m))
RoIC = -47.70% (negative operating profit) (NOPAT -391.2m / Invested Capital 820.3m)
WACC = 6.05% (E(682.3m)/V(1.39b) * Re(12.08%) + D(703.1m)/V(1.39b) * Rd(0.25%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 6.12%
Fair Price DCF = unknown (Cash Flow -131.3m)
EPS Correlation: 64.43 | EPS CAGR: 23.99% | SUE: 0.97 | # QB: 1
Revenue Correlation: 28.14 | Revenue CAGR: 1.75% | SUE: -0.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.13 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.51 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+11.8%